CDK2 and neoplasm: Pharmacophores such as 1,3‐thiazolidin‐4‐ones and bis‐(6‐pyrazolyltriazolo‐thiadiazine) derivatives can effectively inhibit CDK2, providing support for strategies that target dysregulated cell cycle pathways in tumor cells [36–38].